Advancing Neurogenetic Diagnoses Through Long-Read Sequencing

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-60
SponsorUniversity Hospital, Bordeaux

About this trial

Nucleotide repeats emerge as one of the most prolific classes of genetic variations. They have the propensity to in-crease in length across generations, and have been implicated in at least 65 known neurological/ neurodevelop-mental and neuromuscular conditions. Simultaneous analysis of all these nucleotide repeats is now possible through the cutting-edge methodologies recently developed that are the long-read sequencing and the optical genome mapping. Investigator propose to test these methodologies in patients carrying expansions in those repeats and to determine the capacity of these technics to detect novel repeats in patients with no genetic diagnosis yet.

Eligibility criteria

Qualifiers

Participants affiliated with or beneficiaries of a social security scheme

Participants who speak French

Participants aged ≥ 6 and ≤ 60 years

Free and informed consent, signed by the parents or the holder of parental authority for patients under the age of 18

Disqualifiers

By the parents or the holder of parental authority for patients under the age of 18

By the patient's representative for adults under guardianship

By the adult patient This opposition from the patient must be communicated to the site investigator within a maximum of one month after the information note has been sent. If the letter confirming consent is returned due to an incorrect address, the patient will not be included.

Degraded DNA or average size < 30 kb

Trial design

Treatments tested in this trial

  • Skin biopsy
  • blood sampling

Treatment groups

304 Participants
are divided into 3 treatment groups

Sponsors and collaborators